Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation
Tóm tắt
To generate biomarkers of target engagement or predictive response for multi-target drugs is challenging. One such compound is the multi-AGC kinase inhibitor AT13148. Metabolic signatures of selective signal transduction inhibitors identified in preclinical models have previously been confirmed in early clinical studies. This study explores whether metabolic signatures could be used as biomarkers for the multi-AGC kinase inhibitor AT13148. To identify metabolomic changes of biomarkers of multi-AGC kinase inhibitor AT13148 in cells, xenograft / mouse models and in patients in a Phase I clinical study. HILIC LC–MS/MS methods and Biocrates AbsoluteIDQ™ p180 kit were used for targeted metabolomics; followed by multivariate data analysis in SIMCA and statistical analysis in Graphpad. Metaboanalyst and String were used for network analysis. BT474 and PC3 cells treated with AT13148 affected metabolites which are in a gene protein metabolite network associated with Nitric oxide synthases (NOS). In mice bearing the human tumour xenografts BT474 and PC3, AT13148 treatment did not produce a common robust tumour specific metabolite change. However, AT13148 treatment of non-tumour bearing mice revealed 45 metabolites that were different from non-treated mice. These changes were also observed in patients at doses where biomarker modulation was observed. Further network analysis of these metabolites indicated enrichment for genes associated with the NOS pathway. The impact of AT13148 on the metabolite changes and the involvement of NOS-AT13148- Asymmetric dimethylarginine (ADMA) interaction were consistent with hypotension observed in patients in higher dose cohorts (160-300 mg). AT13148 affects metabolites associated with NOS in cells, mice and patients which is consistent with the clinical dose-limiting hypotension.
Tài liệu tham khảo
Ang, J. E., Pal, A., Asad, Y. J., Henley, A. T., Valenti, M., Box, G., et al. (2017). Modulation of plasma metabolite biomarkers of the MAPK pathway with MEK inhibitor RO4987655: Pharmacodynamic and predictive potential in metastatic melanoma. Molecular Cancer Therapeutics,16, 2315–2323.
Ang, J. E., Pandher, R., Ang, J. C., Asad, Y. J., Henley, A. T., Valenti, M., et al. (2016). Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: Preclinical discovery to Phase I trial evaluation. Molecular Cancer Therapeutics,15, 1412–1424.
Banerji, U., Dean, E. J., Perez-Fidalgo, J. A., Batist, G., Bedard, P. L., You, B., et al. (2018). A Phase I Open-Label study to identify a dosing regimen of the Pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-Mutated breast and gynecologic cancers. Clinical Cancer Research,24(9), 2050–2059.
Bivona, T. G., & Philips, M. R. (2003). Ras pathway signaling on endomembranes. Current Opinion in Cell Biology,15, 136–142.
Fulton, D., Babbitt, R., Zoellner, S., Fontana, J., Acevedo, L., McCabe, T. J., et al. (2004). Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release. Journal of Biological Chemistry,279, 30349–30357.
Griffiths, W. J., Koal, T., Wang, Y., Kohl, M., Enot, D. P., & Deigner, H. P. (2010). Targeted metabolomics for biomarker discovery. Angewandte Chemie (International ed. in English),49, 5426–5445.
Sibal, L., Agarwal, S. C., Home, P. D., & Boger, R. H. (2010). The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and Cardiovascular Disease. Current Cardiology Reviews.,6(2), 82–90.
Leiper, J., & Vallance, P. (2006). New tricks from an old dog: nitric oxide-independent effects of dimethylarginine dimethylaminohydrolase. Arteriosclerosis, Thrombosis, and Vascular Biology,26, 1419–1420.
Liao, J. K., Seto, M., & Noma, K. (2007). Rho kinase (ROCK) inhibitors. Journal of Cardiovascular Pharmacology,50, 17–24.
Ming, X. F., Viswambharan, H., Barandier, C., Ruffieux, J., Kaibuchi, K., Rusconi, S., et al. (2002). Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Molecular and Cellular Biology,22, 8467–8477.
Murakami, T., Kajikawa, R., Nakamura, H., Nishida, T., Yoshimura, K., Yoshihara, T., et al. (2019). Intra-arterial infusion of fasudil hydrochloride to treat post-traumatic cerebral vasospasm. Acute Med Surg,6, 392–395.
Pearce, L. R., Komander, D., & Alessi, D. R. (2010). The nuts and bolts of AGC protein kinases. Nature Reviews Molecular Cell Biology,11, 9–22.
Rath, N., Munro, J., Cutiongco, M. F., Jagiello, A., Gadegaard, N., McGarry, L., et al. (2018). Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Cancer Research,78(12), 3321–3336.
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., et al. (2015). First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clinical Cancer Research,21, 77–86.
Sassone-Corsi, P. (2012). The cyclic AMP pathway. Cold Spring Harb Perspect Biol.,4(12), a011148.
Sato, M., Ueda, Y., Takagi, T., & Umezawa, Y. (2003). Production of PtdInsP3 at endomembranes is triggered by receptor endocytosis. Nature Cell Biology,5, 1016–1022.
Shina, S., Funga, S.-M., Mohana, S., & Funga, H.-L. (2011). Simultaneous Bioanalysis of L_Arginine, L-Citrulline, and Dimethylarginines by LC-MSMS. J Chromatogr B Analyt Technol Biomed Life Sci.,879(7–8), 467–474.
Stow, J. L., & Heimann, K. (1998). Vesicle budding on Golgi membranes: regulation by G proteins and myosin motors. Biochimica et Biophysica Acta,1404, 161–171.
Tran, C. T. L., Leiper, J. M., & Vallance, P. (2003). The DDAH/ADMA/NOS pathway. Atherosclerosis Supplements,4, 33–40.
Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., et al. (2010). Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer,102, 1555–1577.
Xi, Y., Niu, J., Shen, Y., Li, D., Peng, X., & Wu, X. (2016). AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochemical and Biophysical Research Communications,478, 330–336.
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019). Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer,18, 26.
Yap, T. A., Walton, M. I., Grimshaw, K. M., Te Poele, R. H., Eve, P. D., Valenti, M. R., et al. (2012). AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clinical Cancer Research,18, 3912–3923.
Yap, T. A., Yan, L., Patnaik, A., Tunariu, N., Biondo, A., Fearen, I., et al. (2014). Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clinical Cancer Research,20, 5672–5685.
Yecies, J. L., Zhang, H. H., Menon, S., Liu, S., Yecies, D., Lipovsky, A. I., et al. (2011). Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metabolism,14, 21–32.
Yuan, M., Breitkopf, S. B., Yang, X., & Asara, J. M. (2012). A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nature Protocols,7, 872–881.